Groundbeaking of vaccine production center in France Groundbeaking of vaccine production center in France Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health
Winners of 2020 BVDzero Case Awards Winners of 2020 BVDzero Case Awards Winners of 2020 BVDzero Case Awards announced. 10 top clinical cases will receive a total prize of 15,000 euros.
New spesolimab data show significant improvement in GPP flares New spesolimab data show significant improvement in GPP flares New spesolimab data show significant improvement in GPP flares
We are Global Top Employer 2024 We are Global Top Employer 2024 Global Top Employer certification reflects our impactful people development with high scores in development and steering practices as well as benefits on employee wellbeing.
Boehringer-Ingelheim's-half-year-figures-2021 Boehringer-Ingelheim's-half-year-figures-2021 Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
Ukraine Help: We fly, we bike, we accommodate Ukraine Help: We fly, we bike, we accommodate The solidarity for Ukraine from Boehringer Ingelheim employees is incredible. Equally impressive is their practical help.
A tool to aid in the prevention of African swine fever A tool to aid in the prevention of African swine fever ASF COMBAT is an online management and biosecurity assessment tool aimed at reducing the African swine fever introduction risk level.
COVID-19 Protecting Our Employees COVID-19 Protecting Our Employees Boehringer Ingelheim has taken precautions to protect the health of employees and mitigate the risk of COVID-19 affecting our organization.
Spesolimab meets key endpoint for GPP flare prevention Spesolimab meets key endpoint for GPP flare prevention Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
Nagoya Protocol Nagoya Protocol At Boehringer Ingelheim, environmental consciousness and protection are priorities in everything we do.
1990-2023: Value through Innovation 1990-2023: Value through Innovation The Boehringer Ingelheim history from 1990 to 2023, with milestones
Why cancer care is personal for us Why cancer care is personal for us At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
reduced-heart-failure-treatment-approval-europe reduced-heart-failure-treatment-approval-europe European approval for treatment of adults with heart failure with reduced ejection fraction
Have you heard about monkeypox Have you heard about monkeypox Monkeypox: What exactly is it, how is the virus transmitted, what are the most noticeable symptoms?
Questions and Answers Questions and Answers Answers to common questions from both patients and health care professionals regarding Compassionate Use of experimental medications.
S&P Animal Health Partnering Oct 2023 S&P Animal Health Partnering Oct 2023 Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
Tips to help you start your patient advocacy journey Tips to help you start your patient advocacy journey Advocating for yourself as a patient can be daunting. Jeff Dunn, President of Union for International Cancer Control (UICC), shares some tips
GPP Interview with Professor Barker GPP Interview with Professor Barker An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
Spesolimab prevents GPP flares Spesolimab prevents GPP flares Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial
Breakthrough Designation granted in US and China Breakthrough Designation granted in US and China SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares
Ethical Business Practices Ethical Business Practices Suppliers shall conduct their business in an ethical manner and act with integrity.